Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP1682Y] to HSD17B1
- Suitable for: WB, Flow Cyt, IP, IHC-P
- Reacts with: Human
Product nameAnti-HSD17B1 antibody [EP1682Y]
See all HSD17B1 primary antibodies
DescriptionRabbit monoclonal [EP1682Y] to HSD17B1
Tested applicationsSuitable for: WB, Flow Cyt, IP, IHC-Pmore details
Unsuitable for: ICC/IF
Species reactivityReacts with: Human
Synthetic peptide within Human HSD17B1 (C terminal). The exact sequence is proprietary.
- WB: Human placenta lysate. IHC-P: Human placenta tissue.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab51045 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Detects a band of approximately 35 kDa (predicted molecular weight: 35 kDa).|
|Flow Cyt||Use 1µg for 106 cells.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|IHC-P||1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionFavors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
PathwaySteroid biosynthesis; estrogen biosynthesis.
Sequence similaritiesBelongs to the short-chain dehydrogenases/reductases (SDR) family.
- Information by UniProt
- 17 beta HSD 1 antibody
- 17 beta hydroxysteroid dehydrogenase type 1 antibody
- 17-beta-HSD 1 antibody
Anti-HSD17B1 antibody [EP1682Y] (ab51045) at 1/100000 dilution + Human placenta lysate at 10 µg
Goat anti-Rabbit HRP labeled. at 1/2000 dilution
Predicted band size: 35 kDa
Observed band size: 35 kDa
Ab51045 (1/100 dilution) staining human HSD17B1 in paraffin embedded human placenta tissue by Immunohistochemistry.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Overlay histogram showing JEG3 cells stained with ab51045 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab51045, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1µg/1x106 cells ) used under the same conditions. Acquisition of >5,000 events was performed.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab51045 has been referenced in 10 publications.
- Li F et al. siRNA-based breast cancer therapy by suppressing 17ß-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo. Drug Des Devel Ther 13:757-766 (2019). PubMed: 30863015
- Konings GF et al. Blocking 17ß-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. J Pathol 244:203-214 (2018). PubMed: 29144553
- Sinreih M et al. The Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial Cancer. Front Pharmacol 8:368 (2017). PubMed: 28690541
- Lassance L et al. Obesity-induced down-regulation of the mitochondrial translocator protein (TSPO) impairs placental steroid production. J Clin Endocrinol Metab 100:E11-8 (2015). PubMed: 25322273
- Rižner TL Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol Cell Endocrinol 381:124-39 (2013). Human . PubMed: 23911898
- Aka JA et al. 17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration. Breast Cancer Res 14:R92 (2012). WB . PubMed: 22691413
- Zhang CY et al. The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells. PLoS One 7:e29835 (2012). WB ; Human . PubMed: 22253796
- Cornel KM et al. Overexpression of 17ß-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17ß-estradiol. J Clin Endocrinol Metab 97:E591-601 (2012). PubMed: 22362820
- Takagi K et al. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer 17:415-30 (2010). PubMed: 20228125
- Margarit L et al. MUC1 as a Discriminator between Endometrium from Fertile and Infertile Patients with PCOS and Endometriosis. J Clin Endocrinol Metab : (2010). PubMed: 20826587